Time filter

Source Type

The present invention relates to a new pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or related compounds for beneficially influencing the intestinal microbiota and blood lipid levels. In certain embodiments, the pharmaceutical composition is partially or entirely released into the lower small intestine and/or large intestine.


Patent
CONARIS Research Institute AG | Date: 2016-12-28

The present invention relates to novel methods and compositions for positively influencing or normalising the human intestinal microbiota. The invented technique is termed intestinal microenvironment transfer (IMEnT) and comprises the preparation of a mixture of metabolites, nutrients and mediators produced by both the intestinal microbiota and the body cells of a healthy animal, especiallymammal, andparticularlypig or human, donor and transfer of this mixture (the IMEnT preparation)to a recipient of the same or another species suffering from intestinal dysbiosis in order to revitalise and/or normalise the recipients endogenous microbiota. In particular, the present invention relates to pharmaceutical compositions and formulations as well as dietary supplements for specific and/or selective delivery of the IMEnT preparations into the small intestine and/or the large intestine.


Waetzig G.H.,CONARIS Research Institute AG | Rose-John S.,University of Kiel
Expert Opinion on Therapeutic Targets | Year: 2012

Introduction: Interleukin-6 (IL-6) is a key target in inflammation and cancer. Selective inhibition of IL-6 trans-signalling could provide the same or even higher therapeutic efficacy with a better side effect profile than complete IL-6 inhibition. Animal studies with IL-6 inhibitors show that the classic IL-6 signalling pathway via the membrane-bound IL-6 receptor (IL-6R) has important physiological functions, whereas blocking the trans-signalling pathway via the soluble IL-6R (sIL-6R) is sufficient to prevent or treat IL-6-driven diseases. Due to the success of the anti-IL-6R antibody tocilizumab and difficulties of constructing selective trans-signalling inhibitors, most drug candidates in clinical development target IL-6 or IL-6R and, thus, both IL-6 pathways. By contrast, the fusion protein sgp130Fc selectively targets IL-6/sIL-6R trans-signalling by utilising the soluble gp130 receptor as the natural inhibitor of trans-signalling. Areas covered: The authors summarise recent developments in the field with a focus on animal studies highlighting the mechanistic differences between classic and trans-signalling and their therapeutic implications. Expert opinion: Characterising disease mechanisms in terms of the employed IL-6 pathways will help to select the right therapeutic IL-6 inhibitor in the future. The trans-signalling inhibitor sgp130Fc is about to enter the clinic and holds promise for a clinically different profile in comparison with complete IL-6 inhibitors. © 2012 Informa UK, Ltd.


Holmer R.,University of Kiel | Goumas F.A.,University of Kiel | Waetzig G.H.,CONARIS Research Institute AG | Rose-John S.,University of Kiel | Kalthoff H.,University of Kiel
Hepatobiliary and Pancreatic Diseases International | Year: 2014

Background Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with a poor prognosis and little treatment options. The development and progression of the disease is fostered by inflammatory cells and cytokines. One of these cytokines is interleukin-6 (IL-6), which plays an important role in a wide range of biologic activities. Data Sources A systematic search of PubMed was performed to identify relevant studies using key words such as interleukin-6, inflammatory cytokines, inflammation and pancreatic cancer or PDAC. Articles related to IL-6 and pancreatic cancer were systematically reviewed. Results IL-6 is elevated in the serum of pancreatic cancer patients and correlates with cachexia, advanced tumor stage and poor survival. Its expression is enhanced by hypoxia and proteins involved in pancreatic cancer development like Kras, mesothelin or ZIP4. IL-6 in turn contributes to the generation of a pro-tumorigenic microenvironment and is probably involved in angiogenesis and metastasis. In experimental mouse models of PDAC, IL-6 was important for the development and progression of precursor lesions. Conclusion IL-6 emerges as a key player in pancreatic cancer development and progression, and hence should be considered as a new therapeutic target. © 2014 The Editorial Board of Hepatobiliary & Pancreatic Diseases International.


The present invention relates to a new pharmaceutical composition containing nicotinic acid, nicotinamide, tryptophanor related compounds for positively influencing the intestinal microbiota. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.


Patent
Conaris Research Institute AG | Date: 2013-12-17

Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala_(234)-Glu_(235)-Gly_(236)-Ala_(237). Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.


Patent
Conaris Research Institute AG | Date: 2015-04-17

Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala_(234)-Glu_(235)-Gly_(236)-Ala_(237). Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.


Patent
CONARIS Research Institute AG | Date: 2016-06-15

The present invention relates to a cartridge that may be a unit for an administration device for medication, such as, e.g., an injector, a pen, an inhalator or a dispenser. The cartridge of the invention enables personalized dosing, and becomes inactivated in case of breaches of cartridge integrity, unauthorised use and/or after use. It preferably enables the extension of the cold chain surveillance to the actual site and time of administration, tracking and tracing. The present invention further enables the interaction of the cartridge with a suitable administration device, leading to completely safe, authorised, traceable, variable, individualised, programmable, remote controlled and/or two-way documentable dosing of administered drug formulations with the added benefit of allowing remote controlled, tamper-proof flat pricing models for variable dosing per patient and time unit.


The present invention relates to a novel use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota, wherein tryptophan levels are preferably measured in blood, plasma or serum.


Patent
Conaris Research Institute AG | Date: 2013-06-20

Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr_(102 )GIn_(113 )or ASn_(114 )of the N-terminal Ig-like domain of gp130 is mutated to Tyr_(102), Phe_(113 )or Leu_(114), respectively. These mutations, alone or in combination, specifically enhance binding of gp130 to its ligand complex of interleukin-6 and soluble interleukin-6 receptor, thus increasing the biological activity of the gp130 muteins. In a particularly preferred embodiment, all three mutations are combined in the triple mutein Thr102Tyr/Gln113Phe/Asn114Leu (T102Y/Q113F/N114L). Moreover, a pharmaceutical composition containing said monomers or dimers and various medical uses are described.

Loading CONARIS Research Institute AG collaborators
Loading CONARIS Research Institute AG collaborators